Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
BackgroundThe impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure.MethodsI...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.851035/full |
| _version_ | 1811235981511098368 |
|---|---|
| author | Luis M. Pérez-Belmonte Luis M. Pérez-Belmonte Luis M. Pérez-Belmonte Jaime Sanz-Cánovas María D. García de Lucas Michele Ricci Beatriz Avilés-Bueno Lidia Cobos-Palacios Miguel A. Pérez-Velasco Almudena López-Sampalo M. Rosa Bernal-López M. Rosa Bernal-López Sergio Jansen-Chaparro José P. Miramontes-González José P. Miramontes-González Ricardo Gómez-Huelgas Ricardo Gómez-Huelgas |
| author_facet | Luis M. Pérez-Belmonte Luis M. Pérez-Belmonte Luis M. Pérez-Belmonte Jaime Sanz-Cánovas María D. García de Lucas Michele Ricci Beatriz Avilés-Bueno Lidia Cobos-Palacios Miguel A. Pérez-Velasco Almudena López-Sampalo M. Rosa Bernal-López M. Rosa Bernal-López Sergio Jansen-Chaparro José P. Miramontes-González José P. Miramontes-González Ricardo Gómez-Huelgas Ricardo Gómez-Huelgas |
| author_sort | Luis M. Pérez-Belmonte |
| collection | DOAJ |
| description | BackgroundThe impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure.MethodsIn this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.ResultsA total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p<0.01), a reduction in the proportion of patients with New York Heart Association functional class III (40.4% to 16.2%, p<0.01), and a reduction in N-terminal pro-brain natriuretic peptide levels (969.5 ± 653.5 vs 577.4 ± 322.1 pg/mL, p<0.01). Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined. Additionally, significant reductions in glycated hemoglobin (-1.4%) and body weight (-12.7 kilograms) were observed as well as a de-intensification of antidiabetic therapy. Moreover, semaglutide was safe and well-tolerated.ConclusionIn obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required. |
| first_indexed | 2024-04-12T12:01:26Z |
| format | Article |
| id | doaj.art-80e2d36af32042089b464947c5cd246c |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-12T12:01:26Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-80e2d36af32042089b464947c5cd246c2022-12-22T03:33:50ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-06-011310.3389/fendo.2022.851035851035Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical PracticeLuis M. Pérez-Belmonte0Luis M. Pérez-Belmonte1Luis M. Pérez-Belmonte2Jaime Sanz-Cánovas3María D. García de Lucas4Michele Ricci5Beatriz Avilés-Bueno6Lidia Cobos-Palacios7Miguel A. Pérez-Velasco8Almudena López-Sampalo9M. Rosa Bernal-López10M. Rosa Bernal-López11Sergio Jansen-Chaparro12José P. Miramontes-González13José P. Miramontes-González14Ricardo Gómez-Huelgas15Ricardo Gómez-Huelgas16Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, SpainServicio de Medicina Interna, Hospital Hospital Helicópteros Sanitarios, Marbella, SpainCentro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, SpainServicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, SpainServicio de Medicina Interna, Hospital Costa del Sol, Marbella, SpainServicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, SpainServicio de Nefrología, Hospital Costal del Sol, Marbella, SpainServicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, SpainServicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, SpainServicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, SpainServicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, SpainCentro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, SpainServicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, SpainServicio de Medicina Interna, Hospital Universitario Rio Hortega, Departamento de Medicina, Facultad de Medicina, Universidad de Valladolid, Valladolid, SpainInstituto de investigaciones biomédicas de Salamanca (IBSAL), Salamanca, SpainServicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, SpainCentro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, SpainBackgroundThe impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure.MethodsIn this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.ResultsA total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p<0.01), a reduction in the proportion of patients with New York Heart Association functional class III (40.4% to 16.2%, p<0.01), and a reduction in N-terminal pro-brain natriuretic peptide levels (969.5 ± 653.5 vs 577.4 ± 322.1 pg/mL, p<0.01). Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined. Additionally, significant reductions in glycated hemoglobin (-1.4%) and body weight (-12.7 kilograms) were observed as well as a de-intensification of antidiabetic therapy. Moreover, semaglutide was safe and well-tolerated.ConclusionIn obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.https://www.frontiersin.org/articles/10.3389/fendo.2022.851035/fullobesitytype 2 diabetesheart failuresemaglutidehealth status |
| spellingShingle | Luis M. Pérez-Belmonte Luis M. Pérez-Belmonte Luis M. Pérez-Belmonte Jaime Sanz-Cánovas María D. García de Lucas Michele Ricci Beatriz Avilés-Bueno Lidia Cobos-Palacios Miguel A. Pérez-Velasco Almudena López-Sampalo M. Rosa Bernal-López M. Rosa Bernal-López Sergio Jansen-Chaparro José P. Miramontes-González José P. Miramontes-González Ricardo Gómez-Huelgas Ricardo Gómez-Huelgas Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice Frontiers in Endocrinology obesity type 2 diabetes heart failure semaglutide health status |
| title | Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice |
| title_full | Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice |
| title_fullStr | Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice |
| title_full_unstemmed | Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice |
| title_short | Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice |
| title_sort | efficacy and safety of semaglutide for the management of obese patients with type 2 diabetes and chronic heart failure in real world clinical practice |
| topic | obesity type 2 diabetes heart failure semaglutide health status |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.851035/full |
| work_keys_str_mv | AT luismperezbelmonte efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT luismperezbelmonte efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT luismperezbelmonte efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT jaimesanzcanovas efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT mariadgarciadelucas efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT michelericci efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT beatrizavilesbueno efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT lidiacobospalacios efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT miguelaperezvelasco efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT almudenalopezsampalo efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT mrosabernallopez efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT mrosabernallopez efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT sergiojansenchaparro efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT josepmiramontesgonzalez efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT josepmiramontesgonzalez efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT ricardogomezhuelgas efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice AT ricardogomezhuelgas efficacyandsafetyofsemaglutideforthemanagementofobesepatientswithtype2diabetesandchronicheartfailureinrealworldclinicalpractice |